Another study targets LAG3 for the first time in a phase I trial [162] on advanced MSS-CRC with anti-LAG-3 antibody MK4280 (Favezelimab) plus Pembrolizumab with promising antitumor activity, differing from the single therapy [162]. Here, LAG3 is linked to colorectal carcinoma.